Source - RNS
RNS Number : 8694J
OptiBiotix Health PLC
14 September 2016

OptiBiotix Health plc

("OptiBiotix" or the "Company")


Holding in Company


The Company was informed on 13 September 2016 that Seneca Partners Limited no longer has a disclosable interest in the Company.



This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:


OptiBiotix Health plc

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP

                 Tel: 020 7148 7900

Liam Murray

Hybridan LLP (Joint Broker)

Tel: 0203 764 2341

Claire Louise Noyce

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001


About OptiBiotix -

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS
The company news service from the London Stock Exchange

Related Charts

Optibiotix Health (OPTI)

0.00 (0.00%)
delayed 05:00AM